Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10995009 | 0.98 | KEAP1 (0.50) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL6387270 | 0.81 | TSHR (0.44) | CYP3A4TSHRTDP1MAPT | |
| SCHEMBL18415154 | 0.81 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL9906166 | 0.81 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL13131231 | 0.81 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL16191309 | 0.81 | CYP2C9 (0.44) | KEAP1NFE2L2CYP2D6CYP2B6CHRM3 | |
| SCHEMBL13429177 | 0.81 | KEAP1 (0.56) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL11868460 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 | |
| SCHEMBL23747060 | 0.79 | CYP19A1 (0.49) | CYP2D6CYP3A4MAPT | |
| SCHEMBL17885865 | 0.79 | KEAP1 (0.46) | KEAP1NFE2L2CHRM2CHRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070262-A1 | DEVICE AND METHOD FOR PRODUCING CUMENE BY HYDROGENOLYSIS OF α,α-DIMETHYLBENZYL ALCOHOL | 万华化学集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20150004484-A1 | ORGANIC ELECTROLYTE AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2797153-A1 | ORGANIC ELECTROLYTE, AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX Nippon Oil & Energy Corporation (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-104011928-A | Organic electrolyte, and organic electrolyte storage battery | JX NIPPON OIL & ENERGY CORP | 2014-08-27 | — | — | CN | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| CN-102190599-A | Phase-transfer catalysis method for preparing 2-substituent-2-benzene glutaronitrile | UNIV NORTHWEST NORMAL | 2011-09-21 | — | — | CN | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-7297754-B2 | Method for the preparation of aromatic chloroformates | GENERAL ELECTRIC COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060293535-A1 | Method for the preparation of aromatic chloroformates | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2006-12-28 | — | — | US | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-5650262-A | High-resolution negative photoresist with wide process latitude | OLIN MICROELECTRONIC CHEMICALS, INC. | 1997-07-22 | — | — | US | disclosed |
| EP-0599779-A1 | High-resolution negative photoresist having extended processing latitude | OCG Microelectronic Materials AG (CH) | 1994-06-01 | — | — | EP | disclosed |
| EP-0037167-B1 | MANUFACTURE OF HYDROPEROXIDES | THE STANDARD OIL COMPANY (US) | 1983-12-14 | — | — | EP | disclosed |
| US-4293719-A | OXIDATION, OXIDATION CATALYSTS, AMINES | THE STANDARD OIL COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293535-A1 | Method for the preparation of aromatic chloroformates | PAH, CYP8B1, HPD | KEAP1 2098/4885NFE2L2 2203/4885CHRM2 2057/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | KEAP1 880/4885NFE2L2 1796/4885CHRM2 659/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | KEAP1 880/4885NFE2L2 1796/4885CHRM2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.